Should Medicare and Medicaid eventually cover new weight loss drugs such as Ozempic and Wegovy? This week, Audacy took a look ...

The data showed patients who took GLP-1 drugs had a much lower risk of developing cancer than those who took DDP-4s.

Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...

Researchers are beginning to wonder whether blockbuster drugs such as Wegovy, Ozempic and Zepbound could play a role in ...

The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk NVO and Eli Lilly LLY, respectively. This ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

The U.S. Food and Drug Administration has cracked down on compounded drugs, which were readily available while the patented ones were in shortage, and many are worried they will lose access to the ...

How a new Trump plan could make science ‘a political football’ The NIH is already in turmoil. Billlions of dol ...

After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs, some U.S.

Hundreds of thousands of people around the world are now on weight loss drugs like Wegovy, known as GLP-1s. The food industry is taking notice too, with big companies leaning into more nutritional ...

Scientists at Sweden’s Karolinska Institutet have discovered a promising new way to tackle obesity and its related conditions ...